NF2: The Wizardry of Merlin

Genes Chromosomes and Cancer

Volumn 38, Issue 4, 2003, Pages 389-399

  Xiao, Guang Hui ^a   Chernoff, Jonathan ^a   Testa, Joseph R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERLIN; RAC PROTEIN;

AUTOSOMAL DOMINANT DISORDER; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; CHROMOSOME 22; GENE FUNCTION; GENE INACTIVATION; HUMAN; INHIBITION KINETICS; METASTASIS; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS 2 GENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; GENES, NEUROFIBROMATOSIS 2; HUMANS; MODELS, GENETIC; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2;

FALCO COLUMBARIUS;

EID: 0345017844     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10282     Document Type: Review

References (103)

1. Andreoli C, Martin M, Le Borgne R, Reggio H, Mangeat P. 1994. Ezrin has properties to self-associate at the plasma membrane. J Cell Sci 107:2509-2521.
2. Aplin AE, Howe A, Alahari SK, Juliano RL. 1998. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 50:197-263.
3. Baser ME, De Rienzo A, Altomare D, Balsara BR, Hedrick NM, Gutmann DH, Pitts LH, Jackler RK, Testa JR. 2002. Neurofibromatosis 2 and malignant mesothelioma. Neurology 59:290-291.
4. Bashour AM, Meng JJ, Ip W, MacCollin M, Ratner N. 2002. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human schwannoma cells. Mol Cell Biol 22:1150-1157.
5. Bianchi AB, Mitsunaga S-I, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, Kley N, Klein-Szanto AJP, Testa JR. 1995. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854-10858.
6. Bourguignon LY, Zhu H, Shao L, Chen YW. 2000a. Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. J Cell Biol 150:177-191.
7. Bourguignon LY, Zhu H, Shao L, Chen YW. 2000b. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem 275:1829-1838.
8. Brault E, Gautreau A, Lamarine M, Callebaut I, Thomas G, Goutebroze L. 2001. Normal membrane localization and actin association of the NF2 tumor suppressor protein are dependent on folding of its N-terminal domain. J Cell Sci 114:1901-1912.
9. Bretscher A, Edwards K, Fehon RG. 2002. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3:586-599.
10. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr. 1999. Stat3 as an oncogene. Cell 98:295-303.
11. Cheng JQ, Lee W-C, Klein MA, Cheng GZ, Jhanwar SC, Testa JR. 1999. Frequent alterations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 24:238-242.
12. den Bakker MA, Riegman PH, Hekman RA, Boersma W, Janssen PJ, van der Kwast TH, Zwarthoff EC. 1995. The product of the NF2 tumour suppressor gene localizes near the plasma membrane and is highly expressed in muscle cells. Oncogene 10:757-763.
13. Eblen ST, Slack JK, Weber MJ, Catling AD. 2002. Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes. Mol Cell Biol 22:6023-6033.
14. Evans DG, Sainio M, Baser ME. 2000. Neurofibromatosis type 2. J Med Genet 37:897-904.
15. Faruqi TR, Gomez D, Bustelo XR, Bar-Sagi D, Reich NC. 2001. Rac1 mediates STAT3 activation by autocrine IL-6. Proc Natl Acad Sci USA 98:9014-9019.
16. Fernandez-Valle C, Tang Y, Ricard J, Rodenas-Ruano A, Taylor A, Hackler E, Biggerstaff J, Iacovelli J. 2002. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 31:354-362.
17. Gary R, Bretscher A. 1995. Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell 6:1061-1075.
18. Gautreau A, Manent J, Fievet B, Louvard D, Giovannini M, Arpin M. 2002. Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem 277:31279-31282.
19. Giovannini M, Robanus-Maandag E, Niwa-Kawakita M, van der Valk M, Woodruff JM, Goutebroze L, Merel P, Berns A, Thomas G. 1999. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev 13:978-986.
20. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G. 2000. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14:1617-1630.
21. Gonzalez-Agosti C, Xu L, Pinney D, Beauchamp R, Hobbs W, Gusella J, Ramesh V. 1996. The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 13:1239-1247.
22. Gunthert U. 1993. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 184:47-63.
23. Gusella JF, Ramesh V, MacCollin M, Jacoby LB. 1996. Neurofibromatosis 2: loss of merlin's protective spell. Curr Opin Genet Dev 6:87-92.
24. Gutmann DH. 2001. The neurofibromatoses: when less is more. Hum Mol Genet 10:747-735.
25. Gutmann DH, Haipek CA, Hoang Lu K. 1999a. Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations. J Neurosci Res 58:706-716.
26. Gutmann DH, Sherman L, Seftor L, Haipek C, Lu KH, Hendrix M. 1999b. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading. Hum Mol Genet 8:267-275.
27. Hall A. 1998. Rho GTPases and the actin cytoskeleton. Science 279:509-514.
28. Hirao M, Sato N, Kondo T, Yonemura S, Monden M, Sasaki T, Takai Y, Tsukita S. 1996. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J Cell Biol 135:37-51.
29. Huang L, Ichimaru E, Pestonjamasp K, Cui X, Nakamura H, Lo GY, Lin FI, Luna EJ, Furthmayr H. 1998. Merlin differs from moesin in binding to F-actin and in its intra- and intermolecular interactions. Biochem Biophys Res Commun 248:548-553.
30. Huynh DP, Pulst SM. 1996. Neurofibromatosis 2 antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells. Oncogene 13:73-84.
31. Ikeda K, Saeki Y, Gonzalez-Agosti C, Ramesh V, Chiocca EA. 1999. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg 91:85-92.
32. Johnson KC, Kissil JL, Fry JL, Jacks T. 2002. Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene 21:5990-5997.
33. Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, Klein JU, Lee RJ, Segall JE, Westwick JK, Der CJ, Pestell RG. 1999. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. J Biol Chem 274:25245-25249.
34. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M. 2002. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16:1060-1065.
35. Kang BS, Cooper DR, Devedjiev Y, Derewenda U, Derewenda ZS. 2002. The structure of the FERM domain of merlin, the neurofibromatosis type 2 gene product. Acta Crystallogr D Biol Crystallogr 58:381-391.
36. Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV. 1997. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 390:632-636.
37. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. 1995. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 15:6443-6453.
38. Kim H, Lim JY, Kim YH, Park SH, Lee KH, Han H, Jeun SS, Lee JH, Rha HK. 2002. Inhibition of ras-mediated activator protein 1 activity and cell growth by merlin. Mol Cells 14:108-114.
39. Kissil JL, Johnson KC, Eckman MS, Jacks T. 2002. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 277:10394-10399.
40. Kley N, Seizinger BR. 1995. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome? Cancer Surv 25:207-218.
41. Knudson AG. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
42. Knudson AG. 1985. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 45:1437-1443.
43. Knudson A. 1995. Asbestos and mesothelioma: genetic lessons from a tragedy. Proc Natl Acad Sci USA 92:10819-10820.
44. Knudson AG. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-162.
45. Koga H, Araki N, Takeshima H, Nishi T, Hirota T, Kimura Y, Nakao S, Saya H. 1998. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain. Oncogene 17:801-810.
46. LaJeunesse DR, McCartney BM, Fehon RG. 1998. Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J Cell Biol 141:1589-1599.
47. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. 2003. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 17:1090-1100.
48. Lambert JM, Lambert QT, Reuther GW, Malliri A, Siderovski DP, Sondek J, Collard JG, Der CJ. 2002. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 4:621-625.
49. Li W, Chong H, Guan KL. 2001. Function of the Rho family GTPases in Ras-stimulated Raf activation. J Biol Chem 276:34728-34737.
50. Lim JY, Kim H, Kim YH, Kim SW, Huh PW, Lee KH, Jeun SS, Rha HK, Kang JK. 2003. Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway. Biochem Biophys Res Commun 302:238-245.
51. Lutchman M, Rouleau GA. 1995. The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res 55:2270-2274.
52. Mackay DJ, Hall A. 1998. Rho GTPases. J Biol Chem 273:20685-20688.
53. Malliri A, van der Kammen RA, Clark K, van der Valk M, Michiels F, Collard JG. 2002. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417:867-871.
54. Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S, Tsukita S. 1998. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 140:647-657.
55. McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. 1997. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev 11:1253-1265.
56. McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, Jacks T. 1998. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 12:1121-1133.
57. Mettouchi A, Klein S, Guo W, Lopez-Lago M, Lemichez E, Westwick JK, Giancotti FG. 2001. Integrin-specific activation of Rac controls progression through the G(I) phase of the cell cycle. Mol Cell 8:115-127.
58. Minden A, Lin A, Claret FX, Abo A, Karin M. 1995. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81:1147-1157.
59. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P. 2001. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15:968-980.
60. Murthy SS, Testa JR. 1999. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 180:150-157.
61. Nguyen R, Reczek D, Bretscher A. 2001. Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J Biol Chem 276:7621-7629.
62. Nimnual AS, Yatsula BA, Bar-Sagi D. 1998. Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. Science 279:560-563.
63. Nobes CD, Hall A. 1995. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81:53-62.
64. Obremski VJ, Hall AM, Fernandez-Valle C. 1998. Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells. J Neurobiol 37:487-501.
65. Pelton PD, Sherman LS, Rizvi TA, Marchionni MA, Wood P, Friedman RA, Ratner N. 1998. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene 17:2195-2209.
66. Price LS, Collard JG. 2001. Regulation of the cytoskeleton by Rho-family GTPases: implications for tumour cell invasion. Semin Cancer Biol 11:167-173.
67. Pruitt K, Der CJ. 2001. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 171:1-10.
68. Reczek D, Bretscher A. 1998. The carboxyl-terminal region of EBP50 binds to a site in the amino-terminal domain of ezrin that is masked in the dormant molecule. J Biol Chem 273:18452-18458.
69. Ridley AJ, Hall A. 1992. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389-399.
70. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. 1992. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70:401-410.
71. Rouleau GA, Wertelecki W, Haines JL, Hobbs WJ, Trofatter JA, Seizinger JA, Martuza RL, Superneau DW, Conneally PM, Gusella JF. 1987. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 329:246-248.
72. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515-521.
73. Sainio M, Zhao R, Heiska L, Turunen O, den Bakker M, Zwarthoff E, Lutchman M, Rouleau GA, Jaashelainen J, Vaheri A, Carpen O. 1997. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci 110:2249-2260.
74. Sato N, Funayama N, Nagafuchi A, Yonemura S, Tsukita S. 1992. A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites. J Cell Sci 103:131-143.
75. Schulze KM, Hanemann CO, Muller HW, Hanenberg H. 2002. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 11:69-76.
76. Scita G, Nordstrom J, Carbone R, Tenca P, Giardina G, Gutkind S, Bjarnegard M, Betsholtz C, Di Fiore PP. 1999. EPS8 and E3B1 transduce signals from Ras to Rac. Nature 401:290-293.
77. Scoles DR, Huynh DP, Morcos PA, Coulsell ER, Robinson NG, Tamanoi F, Pulst SM. 1998. Neurofibromatosis 2 tumour suppressor schwannomin interacts with beta II-spectrin. Nat Genet 18:354-359.
78. Scoles DR, Huynh DP, Chen MS, Burke SP, Gutmann DH, Pulst SM. 2000. The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet 9:1567-1574.
79. Scoles DR, Nguyen VD, Qin Y, Sun CX, Morrison H, Gutmann DH, Pulst SM. 2002. Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet 11:3179-3189.
80. Sekido Y, Pass HI, Bader S, Mew DJY, Christman MF, Gazdar AF, Minna JD. 1995. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227-1231.
81. Shaw LM, Rabinovitz I, Wang HH, Toker A, Mercurio AM. 1997. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell 91:949-960.
82. Shaw RJ, McClatchey AI, Jacks T. 1998a. Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin. Cell Growth Differ 9:287-296.
83. Shaw RJ, McClatchey AI, Jacks T. 1998b. Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol Chem 273:7757-7764.
84. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan JP, Gupta V, Ratner N, Der CJ, Jacks T, McClatchey AI. 2001. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 1:63-72.
85. Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H, Herrlich P, Gutmann DH. 1997. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15:2505-2509.
86. Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1502.
87. Shimizu T, Seto A, Maita N, Hamada K, Tsukita S, Hakoshima T. 2002. Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J Biol Chem 277:10332-10336.
88. Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH, Guan KL. 2000. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 290:144-147.
89. Speck O, Hughes SC, Noren NK, Kulikauskas RM, Fehon RG. 2003. Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity. Nature 421:83-87.
90. Stokowski RP, Cox DR. 2000. Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations. Am J Hum Genet 66:873-891.
91. Sulciner DJ, Irani K, Yu ZX, Ferrans VJ, Goldschmidt-Clermont P, Finkel T. 1996. rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-kappaB activation. Mol Cell Biol 16:7115-7121.
92. Sun CX, Haipek C, Scoles DR, Pulst SM, Giovannini M, Komada M, Gutmann DH. 2002. Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet 11:3167-3178.
93. Takeshinia H, Izawa I, Lee PS, Safdar N, Levin VA, Sava H. 1994. Detection of cellular proteins that interact with the NF2 tumor suppressor gene product. Oncogene 9:2135-2144.
94. Tikoo A, Varga M, Ramesh V, Gusella J, Maruta H. 1994. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 269:23387-23390.
95. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Hasse V, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF. 1993. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75:791-800.
96. Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S. 1994. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 126:391-401.
97. Tsukita S, Yonemura S, Tsukita S. 1997. ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci 22:53-58.
98. Turner CE. 2000. Paxillin interactions. J Cell Sci 113:4139-4140.
99. Turunen O, Wahlstrom T, Vaheri A. 1994. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol 126:1445-1453.
100. Westwick JK, Lambert QT, Clark GJ, Symons M, Van Aelst L, Pestell RG, Der CJ. 1997. Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Mol Cell Biol 17:1324-1335.
101. Xiao GH, Beeser A, Chernoff J, Testa JR. 2002. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 277:883-886.
102. Xu HM, Gutmann DH. 1998. Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res 51:403-415.
103. Zang KD. 1982. Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet 6:249-274.